CINGW
Cingulate Inc.
Price Chart
Latest Quote
$0.02
-0.00 (-10.82%)
Current Price
| Previous Close | $0.03 |
| Open | $0.04 |
| Day High | $0.02 |
| Day Low | $0.02 |
| Volume | 31,248 |
Stock Information
| Total Debt | $7.43M |
| Cash Equivalents | $25.89M |
| Net Income | $-27.91M |
| EPS (TTM) | $-1.73 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-27.91M |
| Book/sh | $1.58 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 2.37 |
| Current Ratio | 2.55 |
| Debt/Eq | 39.38 |
Returns & Margins
| ROA | -69.68% |
| ROE | -225.11% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.02 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| RSI | nan |
| ATR | nan |
| Shares Float | 12.94M |
| Volatility | -0.85 |
| Rel Volume | 20.00 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| YTD | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $nan | 31,248 |
| 2026-06-12 | $0.06 | 0 |
| 2026-06-11 | $0.06 | 0 |
| 2026-06-10 | $0.06 | 0 |
| 2026-06-09 | $0.06 | 0 |
| 2026-06-08 | $0.06 | 0 |
| 2026-06-05 | $0.06 | 0 |
| 2026-06-04 | $0.06 | 0 |
| 2026-06-03 | $0.06 | 0 |
| 2026-06-02 | $0.06 | 0 |
| 2026-06-01 | $0.06 | 0 |
| 2026-05-29 | $0.06 | 0 |
| 2026-05-28 | $0.06 | 0 |
| 2026-05-27 | $0.06 | 0 |
| 2026-05-26 | $0.06 | 0 |
| 2026-05-22 | $0.06 | 0 |
| 2026-05-21 | $0.06 | 0 |
| 2026-05-20 | $0.06 | 0 |
| 2026-05-19 | $0.06 | 0 |
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $19,938,057 | $15,645,265 | $22,759,304 | $17,502,280 |
| Rent Expense Supplemental | $327,000 | $346,000 | $496,000 | $478,000 |
| Other Income Expense | $-1,150,673 | $-1,013,868 | - | - |
| Net Non Operating Interest Income Expense | $-1,361,130 | $99,236 | $-775,758 | $-174,514 |
| Total Other Finance Cost | $1,361,130 | $-99,236 | $775,758 | $174,514 |
| Operating Expense | $19,938,057 | $15,645,265 | $22,759,304 | $17,502,280 |
| General And Administrative Expense | $10,164,000 | $6,200,000 | $7,266,000 | $8,507,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Net Interest Income | $-1,361,130 | $99,236 | $-775,758 | $-174,514 |
| Normalized Income | $-21,299,238 | $-15,545,737 | $-23,534,947 | $-17,676,232 |
| Net Income From Continuing And Discontinued Operation | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Total Operating Income As Reported | $-19,938,108 | $-15,644,973 | $-22,759,189 | $-17,501,718 |
| Net Income Common Stockholders | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Net Income | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Net Income Including Noncontrolling Interests | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Net Income Continuous Operations | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Pretax Income | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Operating Income | $-19,938,057 | $-15,645,265 | $-22,759,304 | $-17,502,280 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-18,246,490 | $-13,978,307 | $-22,176,386 | $-17,108,269 |
| Total Unusual Items | $-1,150,673 | $-1,013,868 | - | - |
| Total Unusual Items Excluding Goodwill | $-1,150,673 | $-1,013,868 | - | - |
| Reconciled Depreciation | $540,894 | $653,090 | $582,918 | $394,011 |
| EBITDA (Bullshit earnings) | $-19,397,163 | $-14,992,175 | $-22,176,386 | $-17,108,269 |
| EBIT | $-19,938,057 | $-15,645,265 | $-22,759,304 | $-17,502,280 |
| Diluted NI Availto Com Stockholders | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $-1,150,673 | $-1,013,868 | - | - |
| Research And Development | $9,774,057 | $9,445,265 | $15,493,304 | $8,995,280 |
| Selling General And Administration | $10,164,000 | $6,200,000 | $7,266,000 | $8,507,000 |
| Other Gand A | $6,104,000 | $3,008,000 | $2,583,000 | $2,828,000 |
| Insurance And Claims | $741,000 | $984,000 | $1,543,000 | $2,611,000 |
| Rent And Landing Fees | $327,000 | $346,000 | $496,000 | $478,000 |
| Salaries And Wages | $2,992,000 | $1,862,000 | $2,644,000 | $2,590,000 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,508,907 | $7,455,505 | $-6,869,429 | $3,882,022 |
| Total Assets | $15,073,263 | $14,864,489 | $3,491,436 | $11,405,057 |
| Total Non Current Assets | $3,065,005 | $2,203,686 | $2,912,842 | $3,535,405 |
| Current Assets | $12,008,258 | $12,660,803 | $578,594 | $7,869,652 |
| Other Current Assets | $20,700 | $54,865 | $20,698 | $20,698 |
| Current Deferred Assets | $59,383 | $0 | $178,780 | $100,339 |
| Prepaid Assets | $966,779 | $368,292 | $312,078 | $2,157,907 |
| Receivables | $8,013 | $26,325 | $14,622 | $234,432 |
| Other Receivables | $8,013 | $26,325 | $14,622 | $234,432 |
| Cash Cash Equivalents And Short Term Investments | $10,953,383 | $12,211,321 | $52,416 | $5,356,276 |
| Cash And Cash Equivalents | $10,953,383 | $12,211,321 | $52,416 | $5,356,276 |
| Debt | ||||
| Total Debt | $8,786,555 | $5,099,079 | $3,510,241 | $5,866,043 |
| Long Term Debt And Capital Lease Obligation | $2,251,731 | $2,436,879 | $135,099 | $510,235 |
| Long Term Debt | $1,151,509 | $2,436,879 | - | - |
| Current Debt And Capital Lease Obligation | $6,534,824 | $2,662,200 | $3,375,142 | $5,355,808 |
| Current Debt | $6,295,960 | $2,527,108 | $3,000,000 | $5,000,000 |
| Other Current Borrowings | $6,295,960 | $2,527,108 | - | - |
| Net Debt | - | - | $2,947,584 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,564,356 | $7,408,984 | $10,360,865 | $7,523,035 |
| Total Non Current Liabilities Net Minority Interest | $2,251,731 | $2,436,879 | $135,099 | $510,235 |
| Current Liabilities | $10,312,625 | $4,972,105 | $10,225,766 | $7,012,800 |
| Payables And Accrued Expenses | $3,322,624 | $1,954,430 | $6,257,602 | $1,481,367 |
| Interest Payable | $563,883 | $15,089 | $290,000 | $292,339 |
| Payables | $2,079,685 | $1,470,280 | $5,319,675 | $819,219 |
| Total Tax Payable | $44,000 | $200,000 | $120,570 | $56,862 |
| Accounts Payable | $2,035,685 | $1,270,280 | $5,199,105 | $762,357 |
| Current Notes Payable | - | $2,527,108 | $3,000,000 | $5,000,000 |
| Other Current Liabilities | - | - | - | $339,755 |
| Equity | ||||
| Common Stock Equity | $2,508,907 | $7,455,505 | $-6,869,429 | $3,882,022 |
| Total Equity Gross Minority Interest | $2,508,907 | $7,455,505 | $-6,869,429 | $3,882,022 |
| Stockholders Equity | $2,508,907 | $7,455,505 | $-6,869,429 | $3,882,022 |
| Gains Losses Not Affecting Retained Earnings | $0 | $0 | - | $0 |
| Retained Earnings | $-132,375,031 | $-109,925,120 | $-92,943,443 | $-69,408,496 |
| Other Equity Adjustments | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $7,250,299 | $3,402,306 | $97,293 | $47,122 |
| Share Issued | $7,250,299 | $3,402,306 | $97,293 | $47,122 |
| Tangible Book Value | $2,508,907 | $7,455,505 | $-6,869,429 | $3,882,022 |
| Invested Capital | $9,956,376 | $12,419,492 | $-3,869,429 | $8,882,022 |
| Working Capital | $1,695,633 | $7,688,698 | $-9,647,172 | $856,852 |
| Capital Lease Obligations | $1,339,086 | $135,092 | $510,241 | $866,043 |
| Total Capitalization | $3,660,416 | $9,892,384 | $-6,869,429 | $3,882,022 |
| Additional Paid In Capital | $134,883,213 | $117,380,285 | $86,074,004 | $73,290,457 |
| Capital Stock | $725 | $340 | $10 | $61 |
| Common Stock | $725 | $340 | $10 | $61 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,100,222 | $0 | $135,099 | $510,235 |
| Current Capital Lease Obligation | $238,864 | $135,092 | $375,142 | $355,808 |
| Pensionand Other Post Retirement Benefit Plans Current | $455,177 | $355,475 | $593,022 | $175,625 |
| Current Accrued Expenses | $1,242,939 | $484,150 | $937,927 | $662,148 |
| Net PPE | $3,065,005 | $2,203,686 | $2,912,842 | $3,535,405 |
| Accumulated Depreciation | $-3,836,968 | $-3,296,074 | $-2,642,984 | $-2,060,066 |
| Gross PPE | $6,901,973 | $5,499,760 | $5,555,826 | $5,595,471 |
| Leases | $474,462 | $474,462 | $471,505 | $471,505 |
| Construction In Progress | $233,397 | $375,278 | $207,976 | $1,739,699 |
| Other Properties | $6,001,366 | $4,457,272 | $4,688,693 | $3,196,615 |
| Machinery Furniture Equipment | $192,748 | $192,748 | $187,652 | $187,652 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | - | - | $0 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,407,320 | $-18,663,187 | $-15,258,639 | $-16,036,228 |
| Operating Activities | ||||
| Operating Cash Flow | $-17,245,182 | $-18,451,387 | $-15,034,543 | $-15,882,808 |
| Cash Flow From Continuing Operating Activities | $-17,245,182 | $-18,451,387 | $-15,034,543 | $-15,882,808 |
| Operating Gains Losses | $1,956,624 | $1,013,868 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-162,138 | $-211,800 | $-224,096 | $-153,420 |
| Investing Cash Flow | $-162,138 | $-211,800 | $-224,096 | $-152,652 |
| Cash Flow From Continuing Investing Activities | $-162,138 | $-211,800 | $-224,096 | $-152,652 |
| Net Other Investing Changes | - | - | - | $-165 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,153,812 | $25,875,168 | $6,970,826 | $0 |
| Financing Cash Flow | $16,149,382 | $30,822,092 | $9,954,779 | $4,898,991 |
| Cash Flow From Continuing Financing Activities | $16,149,382 | $30,822,092 | $9,954,779 | $4,898,991 |
| Net Common Stock Issuance | $10,153,812 | $25,875,168 | $6,970,826 | $0 |
| Common Stock Issuance | $10,153,812 | $25,875,168 | $6,970,826 | $0 |
| Net Other Financing Charges | - | - | - | $-85,919 |
| Other | ||||
| Repayment Of Debt | $-4,430 | $-17,063 | $-16,047 | $-15,090 |
| Issuance Of Debt | $6,000,000 | $4,963,987 | $3,000,000 | $5,000,000 |
| Interest Paid Supplemental Data | $19,895 | $6,288 | $19,421 | $19,000 |
| End Cash Position | $10,953,383 | $12,211,321 | $52,416 | $5,356,276 |
| Beginning Cash Position | $12,211,321 | $52,416 | $5,356,276 | $16,492,745 |
| Changes In Cash | $-1,257,938 | $12,158,905 | $-5,303,860 | $-11,136,469 |
| Net Issuance Payments Of Debt | $5,995,570 | $4,946,924 | $2,983,953 | $4,984,910 |
| Net Long Term Debt Issuance | $5,995,570 | $4,946,924 | $2,983,953 | $4,984,910 |
| Long Term Debt Payments | $-4,430 | $-17,063 | $-16,047 | $-15,090 |
| Long Term Debt Issuance | $6,000,000 | $4,963,987 | $3,000,000 | $5,000,000 |
| Net PPE Purchase And Sale | $-162,138 | $-211,800 | $-224,096 | $-153,420 |
| Purchase Of PPE | $-162,138 | $-211,800 | $-224,096 | $-153,420 |
| Change In Working Capital | $830,852 | $-4,554,224 | $7,104,816 | $598,617 |
| Change In Other Current Liabilities | $1,208,424 | $-358,087 | $-339,755 | $-295,595 |
| Change In Other Current Assets | $-1,240,075 | $267,886 | $263,741 | $227,982 |
| Change In Payables And Accrued Expense | $1,467,896 | $-4,540,719 | $5,193,632 | $791,005 |
| Change In Prepaid Assets | $-623,705 | $88,399 | $1,767,388 | $-580,591 |
| Change In Receivables | $18,312 | $-11,703 | $219,810 | $455,816 |
| Other Non Cash Items | $352,531 | - | - | - |
| Stock Based Compensation | $1,523,828 | $995,484 | $812,670 | $800,796 |
| Depreciation Amortization Depletion | $540,894 | $653,090 | $582,918 | $394,011 |
| Depreciation And Amortization | $540,894 | $653,090 | $582,918 | $394,011 |
| Depreciation | $540,894 | $653,090 | $582,918 | $394,011 |
| Gain Loss On Investment Securities | $1,150,673 | $1,013,868 | - | - |
| Net Income From Continuing Operations | $-22,449,911 | $-16,559,605 | $-23,534,947 | $-17,676,232 |
| Net Short Term Debt Issuance | - | - | $3,000,000 | $0 |
| Short Term Debt Issuance | - | - | $3,000,000 | $5,000,000 |
| Net Investment Purchase And Sale | - | - | $0 | $933 |
| Sale Of Investment | - | - | $0 | $933 |
| Short Term Debt Payments | - | - | - | $0 |
| Purchase Of Investment | - | - | - | - |
Fetched: 2026-06-14